Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 7, 2023
Discovery & Translation

Zhang team discovers new CRISPR-Cas systems; plus E3 ligase targets and more

BioCentury’s roundup of translational innovations
BioCentury | Nov 16, 2017
Tools & Techniques

Yeast against aggregation

How yeast could provide new targets for neurodegenerative diseases
BioCentury | May 31, 2017
Distillery Therapeutics

Hepatic; endocrine / metabolic

BioCentury | Apr 25, 2016
Emerging Company Profile

Yeast on the brain

How Yumanity's platforms allow it to uncover novel neurology targets
BioCentury | Feb 15, 2016
Finance

Breaking from tradition

Why Tony Coles' Yumanity assembled a non-traditional series A syndicate
BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Various

BioCentury | Dec 5, 2013
Distillery Therapeutics

Indication: Neurology

BioCentury | Aug 30, 2012
Distillery Therapeutics

Indication: Neurology

Items per page:
1 - 8 of 8